Abstract
Non-small cell lung cancer (NSCLC) remains the leading cause of cancer-related mortality in the United States. Therapeutic agents that target the underlying biology of this disease are necessary to improve outcomes. Angiogenesis plays a central role in NSCLC tumor growth and metastases. The vascular endothelial growth factor pathway (VEGF) as a therapeutic target was recently validated in NSCLC. Since then, a multitude of early phase clinical trials that incorporate the use of angiogenesis inhibitors, either as single agents or in combination with cytotoxic chemotherapy, have been conducted in advanced, refractory NSCLC. This article reviews these clinical trials with attention to toxicity, efficacy, and direction of further study. The data from these trials suggest that optimal use of antiangiogenic agents in NSCLC is more likely in combination with standard cytotoxic agents, however the most effective combination with the least toxicity is yet to be determined.
Reviews on Recent Clinical Trials
Title: Vascular Endothelial Growth Factor Receptor Tyrosine Kinase Inhibitors in Non-Small Cell Lung Cancer: A Review of Recent Clinical Trials
Volume: 2 Issue: 2
Author(s): Carrie B. Lee and Mark A. Socinski
Affiliation:
Keywords: Sunitinib, Vatalanib, Sorafenib, AMG 706, AZD2171
Abstract: Non-small cell lung cancer (NSCLC) remains the leading cause of cancer-related mortality in the United States. Therapeutic agents that target the underlying biology of this disease are necessary to improve outcomes. Angiogenesis plays a central role in NSCLC tumor growth and metastases. The vascular endothelial growth factor pathway (VEGF) as a therapeutic target was recently validated in NSCLC. Since then, a multitude of early phase clinical trials that incorporate the use of angiogenesis inhibitors, either as single agents or in combination with cytotoxic chemotherapy, have been conducted in advanced, refractory NSCLC. This article reviews these clinical trials with attention to toxicity, efficacy, and direction of further study. The data from these trials suggest that optimal use of antiangiogenic agents in NSCLC is more likely in combination with standard cytotoxic agents, however the most effective combination with the least toxicity is yet to be determined.
Export Options
About this article
Cite this article as:
Lee B. Carrie and Socinski A. Mark, Vascular Endothelial Growth Factor Receptor Tyrosine Kinase Inhibitors in Non-Small Cell Lung Cancer: A Review of Recent Clinical Trials, Reviews on Recent Clinical Trials 2007; 2 (2) . https://dx.doi.org/10.2174/157488707780599401
DOI https://dx.doi.org/10.2174/157488707780599401 |
Print ISSN 1574-8871 |
Publisher Name Bentham Science Publisher |
Online ISSN 1876-1038 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Apoptosis in Anthracycline Cardiomyopathy
Current Pediatric Reviews Gene Therapy for Haemophagocytic Lymphohistiocytosis
Current Gene Therapy Novel Approaches to Study the Involvement of α7-nAChR in Human Diseases
Current Drug Targets The Chemical Structure and Bioactivity of Cycloartane-type Compounds
Current Organic Chemistry Newly Identified Tumor Antigens as Promising Cancer Vaccine Targets for Malignant Melanoma Treatment
Current Topics in Medicinal Chemistry Synthesis and Applications of Hydrogels in Cancer Therapy
Anti-Cancer Agents in Medicinal Chemistry Current Therapeutic Leads for the Treatment of Melanoma: Targeted Immunotherapy in the Post-genomic Era
Current Molecular Pharmacology Network-Based Strategies Can Help Mono- and Poly-pharmacology Drug Discovery: A Systems Biology View
Current Pharmaceutical Design Strategies for the Design of Potent and Selective Kinase Inhibitors
Current Pharmaceutical Design CT-707 Overcomes Resistance of Crizotinib through Activating PDPK1- AKT1 Pathway by Targeting FAK
Current Cancer Drug Targets Therapeutic Proteins in Tumors and Targeted Therapeutic Agents for Cancer Patients
Protein & Peptide Letters Biochemical and Pharmaceutic Properties of Genus <i>Phyllanthus</i> spp.: Focus on <i>P. amarus</i> Schum. & Thonn. and <i>P. niruri</i> L.
Current Traditional Medicine Anti-VEGF Mediated Immunomodulatory Role of Phytochemicals: Scientific Exposition for Plausible HCC Treatment
Current Drug Targets Quercetin as a Systemic Chemopreventative Agent: Structural and Functional Mechanisms
Mini-Reviews in Medicinal Chemistry Current Protein-based Anti-angiogenic Therapeutics
Mini-Reviews in Medicinal Chemistry Targeting of Cancer-Related Proteins with PNA Oligomers
Current Cancer Drug Targets Advances in the Treatment of Ovarian Cancer Using PARP Inhibitors and the Underlying Mechanism of Resistance
Current Drug Targets Development of New Drugs for COPD
Current Medicinal Chemistry Single-Cell Sequencing for Drug Discovery and Drug Development
Current Topics in Medicinal Chemistry The Biphasic Expression Pattern of miR-200a and E-cadherin in Epithelial Ovarian Cancer and its Correlation with Clinicopathological Features
Current Pharmaceutical Design